XFOR: X4 Pharmaceuticals Inc. Stocks News on June 22, 2025

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

XFOR

GlobeNewswire

6 days ago

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

XFOR

GlobeNewswire

12 days ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR

GlobeNewswire

19 days ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

XFOR

GlobeNewswire

a month ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

XFOR

GuruFocus.com

2 months ago

X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...

XFOR

Associated Press Finance

2 months ago

X4 Pharmaceuticals: Q1 Earnings Snapshot

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

XFOR

GlobeNewswire

2 months ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

XFOR

Insider Monkey

2 months ago

Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

XFOR

GlobeNewswire

2 months ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Announces Reverse Stock Split

XFOR

GlobeNewswire

2 months ago

X4 Pharmaceuticals Announces Reverse Stock Split

XFOR

GlobeNewswire

2 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR

Zacks Small Cap Research

3 months ago

XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25…

XFOR

GuruFocus.com

3 months ago

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ...

XFOR

Thomson Reuters StreetEvents

3 months ago

Q4 2024 X4 Pharmaceuticals Inc Earnings Call

XFOR

Associated Press Finance

3 months ago

X4 Pharmaceuticals: Q4 Earnings Snapshot

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

XFOR

GlobeNewswire

3 months ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

XFOR

GuruFocus.com

3 months ago

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: What To Look For

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

XFOR

GlobeNewswire

3 months ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

X4 and taiba to distribute WHIM syndrome therapy in Middle East

XFOR

Pharmaceutical Technology

4 months ago

X4 and taiba to distribute WHIM syndrome therapy in Middle East

XFOR

MT Newswires

4 months ago

X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

XFOR

GlobeNewswire

4 months ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty

XFOR

BioPharma Dive

4 months ago

Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty

XFOR

MT Newswires

4 months ago

X4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

XFOR

GlobeNewswire

5 months ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

XFOR

GlobeNewswire

5 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR

MT Newswires

5 months ago

X4 Pharmaceuticals Says Marketing Application for Mavorixafor Validated for Review by EU Regulator

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

XFOR

GlobeNewswire

5 months ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

January 2025's Top US Penny Stocks To Consider

XFOR

Simply Wall St.

5 months ago

January 2025's Top US Penny Stocks To Consider

XFOR

Zacks Small Cap Research

5 months ago

XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine…

XFOR

MT Newswires

5 months ago

X4 Pharmaceuticals Partners With Norgine to Commercialize Immunotherapy in Europe, Other Regions

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

XFOR

GlobeNewswire

5 months ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Grace Therapeutics And 2 Other US Penny Stocks Worth Watching

XFOR

Simply Wall St.

6 months ago

Grace Therapeutics And 2 Other US Penny Stocks Worth Watching

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

XFOR

GlobeNewswire

7 months ago

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

XFOR

GlobeNewswire

7 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference

XFOR

GlobeNewswire

7 months ago

X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference

Spotlight On 3 US Penny Stocks With At Least $60M Market Cap

XFOR

Simply Wall St.

7 months ago

Spotlight On 3 US Penny Stocks With At Least $60M Market Cap

XFOR

Zacks Small Cap Research

7 months ago

XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia…

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

XFOR

GlobeNewswire

7 months ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

XFOR

GuruFocus.com

7 months ago

X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ...

XFOR

Associated Press Finance

7 months ago

X4 Pharmaceuticals: Q3 Earnings Snapshot

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

XFOR

GlobeNewswire

7 months ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

XFOR

GlobeNewswire

7 months ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

The people-first approach transforming eClinical processes

XFOR

Pharmaceutical Technology

7 months ago

The people-first approach transforming eClinical processes

XFOR

Clinical Trials Arena

7 months ago

The people-first approach transforming eClinical processes

XFOR

GlobeNewswire

8 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

XFOR

GlobeNewswire

8 months ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

XFOR

GlobeNewswire

9 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR

Simply Wall St.

9 months ago

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a favorite amongst institutional investors who own 51%

XFOR

GlobeNewswire

10 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

XFOR

GlobeNewswire

10 months ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

XFOR

Zacks Small Cap Research

10 months ago

XFOR: First Commercial Sales of XOLREMDI™…

XFOR

Associated Press Finance

10 months ago

X4 Pharmaceuticals: Q2 Earnings Snapshot

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

XFOR

GlobeNewswire

10 months ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024

XFOR

Zacks Small Cap Research

a year ago

XFOR: Positive Interim Data from Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia Patients…

XFOR

MT Newswires

a year ago

X4 Pharmaceuticals Shares Fall After Trail Data Announced on Chronic Blood Disease Treatment

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

XFOR

MT Newswires

a year ago

Sector Update: Health Care Stocks Higher Late Afternoon

XFOR

MT Newswires

a year ago

X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

XFOR

Insider Monkey

a year ago

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript

XFOR

Zacks Small Cap Research

a year ago

XFOR: Data from Phase 2 CN Trial Expected in June 2024…

XFOR

GuruFocus.com

a year ago

X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...

XFOR

Associated Press Finance

a year ago

X4 Pharmaceuticals: Q1 Earnings Snapshot

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

XFOR

Zacks Small Cap Research

a year ago

XFOR: XOLREMDI™ Approved by FDA…

XFOR

MT Newswires

a year ago

X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome

XFOR

Reuters

a year ago

UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

XFOR

Simply Wall St.

a year ago

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR

Zacks Small Cap Research

a year ago

XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

XFOR

Insider Monkey

a year ago

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript

XFOR

Thomson Reuters StreetEvents

a year ago

Q4 2023 X4 Pharmaceuticals Inc Earnings Call

XFOR

GuruFocus.com

a year ago

X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Which Pot Stock Will Climb in 2024: Green Thumb Industries vs. Aurora Cannabis

XFOR

Motley Fool

a year ago

Which Pot Stock Will Climb in 2024: Green Thumb Industries vs. Aurora Cannabis

XFOR

GlobeNewswire

a year ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aurora Cannabis Provides Business Update and Announces Date of Third Quarter Fiscal Year 2024 Investor Conference Call

XFOR

PR Newswire

a year ago

Aurora Cannabis Provides Business Update and Announces Date of Third Quarter Fiscal Year 2024 Investor Conference Call

Quad Continues Stock Repurchases in Fourth Quarter 2023

XFOR

Business Wire

a year ago

Quad Continues Stock Repurchases in Fourth Quarter 2023

IARPA Selects BlackSky Spectra® Software Platform as Leading Space-Based AI Approach for Bringing Speed and Scalability to Broad Area Search Mission

XFOR

Business Wire

a year ago

IARPA Selects BlackSky Spectra® Software Platform as Leading Space-Based AI Approach for Bringing Speed and Scalability to Broad Area Search Mission

ZIM (ZIM) Moves 7.5% Higher: Will This Strength Last?

XFOR

Zacks

a year ago

ZIM (ZIM) Moves 7.5% Higher: Will This Strength Last?

Amazon terminates iRobot deal, sees 'no path' to EU approval

XFOR

Yahoo Finance Video

a year ago

Amazon terminates iRobot deal, sees 'no path' to EU approval

Princeton Bancorp (BPRN) Q4 Earnings Surpass Estimates

XFOR

Zacks

a year ago

Princeton Bancorp (BPRN) Q4 Earnings Surpass Estimates

XFOR

Newsfile

a year ago

FingerMotion, Inc. Announces Participation in The Microcap Conference

KNOT Offshore Partners LP Announces Fourth Quarter 2023 Earnings Results Conference Call

XFOR

Business Wire

a year ago

KNOT Offshore Partners LP Announces Fourth Quarter 2023 Earnings Results Conference Call

AMMO, Inc. Announces International Supply Agreement with ZRODelta

XFOR

GlobeNewswire

a year ago

AMMO, Inc. Announces International Supply Agreement with ZRODelta

XFOR

GlobeNewswire

a year ago

National Bankshares, Inc. Announces Agreement to Acquire Frontier Community Bank

Institutions own 21% of Hawthorn Bancshares, Inc. (NASDAQ:HWBK) shares but retail investors control 56% of the company

XFOR

Simply Wall St.

a year ago

Institutions own 21% of Hawthorn Bancshares, Inc. (NASDAQ:HWBK) shares but retail investors control 56% of the company

Turtle Beach (HEAR) Soars 11.9%: Is Further Upside Left in the Stock?

XFOR

Zacks

a year ago

Latest X4 Pharmaceuticals Inc. (XFOR) News on June 22, 2025

Share on Social Networks: